Group of CytoDyn Stockholders Shares Strategic Plan to Obtain Cancer Therapy Approval for Leronlimab
NEW YORK--(BUSINESS WIRE)--A group of long-time stockholders (the “Nominating Stockholders” or the “Group”) of CytoDyn Inc. (“CYDY or the “Company”) (OTC: CYDY) that has nominated five highly ...
PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) has revealed significant progress in its pipeline and operations, underscoring its focus on advancing rese-cel, a cell therapy candidate for ...
SUZHOU, China--(BUSINESS WIRE)--Suzhou Porton Advanced Solutions Ltd. (‘Porton Advanced’) and Guizhou Sinorda Biomedicine Co. Ltd (‘Sinorda Biomedicine’) today announced a long-term strategic ...
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) reported its second-quarter 2025 results, showcasing clinical progress in gene therapy, new strategic partnerships, and a planned spin-off to sharpen its ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback